Purpose Brands Welcomes Dr. B to Help U.S. Consumers Tap HSA/FSA Plans for Memberships at Anytime Fitness, Orangetheory Fitness, Basecamp Fitness, The Bar Method
BOCA RATON, Fla. and WOODBURY, Minn., July 30, 2025 /PRNewswire/ — Consumers across the U.S. who seek the benefits of fitness as part of their preventive health and longevity plans can now tap into the Dr. B telehealth service, making it easier to use their HSA/FSA dollars to join any of the fitness brands in the Purpose Brands portfolio. The service is available today via AnytimeFitness.com, Orangetheory.com and BasecampFitness.com. The Bar Method will offer the Dr. B service before the end of 2025.
'Exercise is medicine, and we must do whatever we can to make it more accessible and affordable for all Americans,' said Nick Herrild, U.S. President, Anytime Fitness. 'Anytime Fitness and our other fitness brands are with our members on every step of their health and wellness journey, and we're thrilled that Dr. B can offer services to help them cover those costs. We need to move fitness more closely to the healthcare equation for all Americans, and this is a strong step in that direction.'
With a streamlined online consultation, Dr. B will help consumers, as well as existing members, determine whether the dollars in their Health Savings Accounts (HSAs) and Flexible Spending Accounts (FSAs) can cover monthly dues for qualifying memberships, personal training services and more.
Anytime Fitness is focused on a personalized fitness and wellness plan for each individual member. Open 24 hours a day, 365 days a year, Anytime Fitness delivers health and wellness training, nutrition, and recovery guidance in the club or via the AF app, plus club membership offers access to more than 5,500 Anytime Fitness clubs in 40 countries and territories and on all seven continents. Members with Apple services can also access Apple Fitness+ content via the AF app.
Orangetheory® Fitness is a heart rate-based group workout that combines science, performance-tracking technology and expert coaching, designed to supercharge metabolism and cardiorespiratory health to help members live a longer, more vibrant life. Each of the workouts is led by a certified coach to ensure members of all fitness and ability levels can be successful and continue to challenge themselves.
Basecamp Fitness is the all-in, high-intensity group workout that packs 50 minutes of supercharged calorie burn into just 35, making it one of the most efficient and effective workouts on the market. Alternating between air bike, floor strength, and an optional 10 minutes of core, members benefit from intense cardio, strength training and abdominal training in every session. The Basecamp app helps members monitor and validate workouts, track results and health data and stay connected with their community.
The Bar Method is built on principles of high-repetition, low-impact resistance training, the science of physical therapy, and an unparalleled teacher training program. Its barre-based approach to personalized, total mind and body fitness blends elements of Pilates, yoga and strength training into a ballet-inspired barre workout that delivers increased strength, endurance and resilience.
Dr.B is a telehealth service that works to make access to healthcare more efficient and equitable, helping patients get affordable care and everyday prescriptions, while expanding access to those who need it most.
'There's no question that exercise plays a huge role in improving health, and we're seeing more and more patients looking into how they can use their HSA or FSA to cover fitness expenses,' said Cyrus Massoumi, founder and CEO, Dr. B. 'We connect people with licensed providers who help determine if fitness can support their health condition, and our platform handles the medical and compliance steps behind the scenes—so patients can trust the process, get the paperwork they need, and focus on feeling their best. We're excited to work with Purpose Brands to help more people access affordable ways to support their health through movement.'
About Dr. BDr. B provides affordable telehealth services that deliver the same care and quality you'd expect to receive from your favorite doctor—without the waiting room. On top of offering $15 consultations for a wide range of conditions and dynamic longevity programs, Dr. B works with fitness industry leaders to bring healthcare and exercise closer together with accessible tools and treatments that promote an active, healthy lifestyle. For more information, visit drb.ai.
About Purpose Brands, LLC Purpose Brands is here to make personal health and wellness accessible for people worldwide. The company holds the world's largest and most trusted portfolio of fitness, health and wellness franchise brands and services: Anytime Fitness, Orangetheory Fitness, Waxing the City, Basecamp Fitness/SUMHIIT Fitness, The Bar Method, Stronger U Nutrition, Healthy Contributions and Provision Security. Together, these brands generate USD$3.7 billion in revenue, operating across 50 countries on all seven continents with a combined 6 million members. With a world-class operating model and suite of services that help its portfolio brands accelerate growth and deliver exceptional member experiences, Purpose Brands is best positioned for rapid expansion and to capture a strong market share in the global wellness industry. For more information, visit PurposeBrands.com.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
New Straits Times
11 hours ago
- New Straits Times
#SHOWBIZ: Justin Timberlake reveals battle with 'relentlessly debilitating' Lyme disease
NEW YORK CITY: Justin Timberlake has disclosed that he was diagnosed with Lyme disease, describing it as "relentlessly debilitating." The singer made the candid revelation in an Instagram post after the final show of his Forget Tomorrow tour in Turkey. The 44-year-old artiste said he had been silently dealing with health issues throughout the tour. "I've been battling some health issues and was diagnosed with Lyme disease. I'm sharing this to shed light on what I've been up against, and not for sympathy," he wrote. Lyme disease is a bacterial infection spread by tick bites that can cause symptoms such as nerve pain, extreme fatigue, and cognitive difficulties. Timberlake said the diagnosis explained the nerve pain and exhaustion he experienced while performing. Despite the challenges, the *NSYNC alum chose to continue with the tour. "The joy that performing brings me far outweighs the fleeting stress my body was feeling. I'm so glad I kept going," he said. Timberlake added that he chose to go public to avoid misunderstandings and to demonstrate his resilience. "I wanted to be transparent, so my struggles wouldn't be misinterpreted. I'm proud of my mental tenacity," he explained. The tour, which began in April 2024, spanned Europe, North America, and Asia. It received mixed reviews, with some critics noting underwhelming performances, which now make more sense in light of his health battle. Timberlake, who has sold over 88 million records and won ten Grammy Awards, is married to actress Jessica Biel, 42. They share two sons, Silas and Phineas. He joins other celebrities like Avril Lavigne and Bella Hadid who have also spoken out about their experiences with Lyme disease. The US public health agency, the Centers for Disease Control and Prevention, estimates that the illness affects nearly half a million Americans each year.
The Sun
21 hours ago
- The Sun
Trump pressures 17 pharma CEOs to cut US drug prices
WASHINGTON: President Donald Trump sent letters to the leaders of 17 major pharmaceutical companies outlining how they should slash U.S. prescription drug prices to match those paid overseas, the White House said on Thursday. Trump signed a sweeping executive order in May demanding drugmakers cut U.S. medicine prices to match those abroad, saying that if companies did not comply, the government could use rulemaking to bring prices down or pursue other measures, such as importing cheaper medicines from overseas. Trump sent the letters to the chief executives of Eli Lilly , Sanofi, Regeneron, Merck & Co , Johnson & Johnson, and AstraZeneca, among others, the White House said. 'Most proposals my Administration has received to 'resolve' this critical issue promised more of the same; shifting blame and requesting policy changes that would result in billions of dollars in handouts to industry,' Trump wrote in the letters, copies of which were posted on his Truth Social account. Shares of Pfizer, Eli Lilly and Gilead Sciences closed down about 2% each, while the NYSE Arca Pharmaceutical Index fell 3% on Thursday. Trump called on drugmakers to provide so-called most-favored-nation prices to every patient enrolled in the government Medicaid health program for low-income people, and to guarantee such pricing for new drugs. The policy is aimed at cutting U.S. prescription drug prices to the lowest possible price paid by members of the Organisation for Economic Co-operation and Development, which includes most of the world's largest economies. Trump also said companies must return excess overseas revenue from raising prices in other countries to offset lower prices in the U.S. to American patients and taxpayers through an agreement with the government. He is requiring drugmakers to stipulate they would not offer other developed nations better prices than what they offer the United States, and said his administration would provide ways to cut out middlemen and sell directly to patients, provided they do so at most-favored-nation prices. Trump gave companies until September 29 to respond with binding commitments to those terms. 'If you refuse to step up, we will deploy every tool in our arsenal to protect Americans from abusive drug pricing practices,' he warned. Analysts, lobbyists and drug pricing experts said it seemed unlikely that the pharmaceutical companies would comply with Trump's demand to lower U.S. prices. 'I might expect them to try to determine if any of their current products might be made available via direct sales (one of the requests) at a lower price than currently available in the U.S.,' said Stacie Dusetzina, professor of health policy at Nashville's Vanderbilt University. UBS analyst Trung Huynh said Trump's letters were a repeat of earlier demands and played down any likely industry impact, calling it 'just another shot in the dark.' Trump has already pushed for voluntary changes and some companies have pledged to build new U.S. manufacturing plants. U.S. patients pay by far the most for prescription medicines, often nearly three times more than in other developed nations. The country also invests heavily in pharmaceutical research and development. Drugmakers have said drastic price cuts would stifle innovation. Pharmaceutical companies including Pfizer, Novartis , AbbVie, and German Merck KGaA's U.S. division, EMD Serono, said they were open to working with the Trump administration. Pfizer is working closely with the Trump Administration and Congress to improve access and affordability for American patients, said spokeswoman Amy Rose. 'Our discussions have been productive,' she said-REUTERS
The Star
21 hours ago
- The Star
US securities regulator lays out sweeping plans to accommodate crypto
FILE PHOTO: Chairman of the Securities and Exchange Commission (SEC) Paul Atkins looks on during his swearing-in ceremony, at the White House in Washington, D.C., U.S., April 22, 2025. REUTERS/Kevin Lamarque/File photo (Reuters) -The head of the U.S. securities regulator unveiled sweeping plans to overhaul capital markets regulations on Thursday to accommodate cryptocurrencies and blockchain-based trading, in a major win for the digital asset industry, which has long pushed for tailored rules. Securities and Exchange Commission Chair Paul Atkins said in remarks that he has directed commission staff to craft guidelines to determine when a crypto token is a security as well as proposals for a wide range of disclosures and exemptions. Atkins also said he has asked SEC staff to work with firms looking to offer tokenized securities -- blockchain-based shares of stocks or funds. "This represents more than a regulatory shift — it is a generational opportunity," Atkins said in a speech before the America First Policy Institute, a think tank that was created to support President Donald Trump's policy agenda. If enacted, Atkins' proposals would represent a broad shift for U.S. securities regulation, potentially enabling crypto to become more enmeshed with traditional finance. Details of his plans for crypto come just a day after a cryptocurrency working group formed by Trump called on the SEC to create new rules specific to digital assets and outlined the administration's stances on market-defining crypto legislation. In a landmark report, the White House encouraged the SEC and the Commodity Futures Trading Commission to use their existing authorities to "immediately enable the trading of digital assets at the federal level." On the campaign trail last year, Trump courted crypto cash by pledging to be a "crypto president" and promote the adoption of digital assets. That is in stark contrast to former Democratic President Joe Biden's regulators, who, in a bid to protect Americans from fraud and money laundering, cracked down on the industry. The Biden administration's SEC sued exchanges Coinbase, Binance, and dozens more, alleging they were flouting U.S. laws. Trump's SEC has since dropped those cases. (Reporting by Hannah Lang in New York; Editing by Aurora Ellis)
